Literature DB >> 22353999

Quantitative modeling of chronic myeloid leukemia: insights from radiobiology.

Tomas Radivoyevitch1, Lynn Hlatky, Julian Landaw, Rainer K Sachs.   

Abstract

Mathematical models of chronic myeloid leukemia (CML) cell population dynamics are being developed to improve CML understanding and treatment. We review such models in light of relevant findings from radiobiology, emphasizing 3 points. First, the CML models almost all assert that the latency time, from CML initiation to diagnosis, is at most ∼10 years. Meanwhile, current radiobiologic estimates, based on Japanese atomic bomb survivor data, indicate a substantially higher maximum, suggesting longer-term relapses and extra resistance mutations. Second, different CML models assume different numbers, between 400 and 10(6), of normal HSCs. Radiobiologic estimates favor values>10(6) for the number of normal cells (often assumed to be the HSCs) that are at risk for a CML-initiating BCR-ABL translocation. Moreover, there is some evidence for an HSC dead-band hypothesis, consistent with HSC numbers being very different across different healthy adults. Third, radiobiologists have found that sporadic (background, age-driven) chromosome translocation incidence increases with age during adulthood. BCR-ABL translocation incidence increasing with age would provide a hitherto underanalyzed contribution to observed background adult-onset CML incidence acceleration with age, and would cast some doubt on stage-number inferences from multistage carcinogenesis models in general.

Entities:  

Mesh:

Year:  2012        PMID: 22353999      PMCID: PMC3362357          DOI: 10.1182/blood-2011-09-381855

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  90 in total

Review 1.  Treatment-related chronic myelogenous leukemia.

Authors:  C F Waller; S Fetscher; W Lange
Journal:  Ann Hematol       Date:  1999-08       Impact factor: 3.673

2.  Translocation frequencies for low to moderate doses remain constant over time.

Authors:  J N Lucas
Journal:  Int J Radiat Biol       Date:  1999-05       Impact factor: 2.694

3.  Long-lasting decrease of marrow and circulating long-term culture initiating cells after allogeneic bone marrow transplant.

Authors:  C Selleri; J P Maciejewski; G De Rosa; A Raiola; A M Risitano; M Picardi; L Pezzullo; L Luciano; P Ricci; G Varriale; P Della Cioppa; L Del Vecchio; B Rotoli
Journal:  Bone Marrow Transplant       Date:  1999-05       Impact factor: 5.483

4.  The topological organization of chromosomes 9 and 22 in cell nuclei has a determinative role in the induction of t(9,22) translocations and in the pathogenesis of t(9,22) leukemias.

Authors:  S Kozubek; E Lukásová; A Marecková; M Skalníková; M Kozubek; E Bártová; V Kroha; E Krahulcová; J Slotová
Journal:  Chromosoma       Date:  1999-12       Impact factor: 4.316

5.  Time-course of translocation and dicentric frequencies in a radiation accident case.

Authors:  M Bauchinger; E Schmid; H Braselmann
Journal:  Int J Radiat Biol       Date:  2001-05       Impact factor: 2.694

6.  Biologically based risk estimation for radiation-induced CML. Inferences from BCR and ABL geometric distributions.

Authors:  T Radivoyevitch; S Kozubek; R K Sachs
Journal:  Radiat Environ Biophys       Date:  2001-03       Impact factor: 1.925

7.  Biologically-based risk estimation for radiation-induced chronic myeloid leukemia.

Authors:  T Radivoyevitch; D G Hoel
Journal:  Radiat Environ Biophys       Date:  2000-09       Impact factor: 1.925

8.  The risk of chronic myeloid leukemia: can the dose-response curve be U-shaped?

Authors:  Tomas Radivoyevitch; Stanislav Kozubek; Rainer K Sachs
Journal:  Radiat Res       Date:  2002-01       Impact factor: 2.841

9.  Modeling the low-LET dose-response of BCR-ABL formation: predicting stem cell numbers from A-bomb data.

Authors:  T Radivoyevitch; D G Hoel
Journal:  Math Biosci       Date:  1999 Nov-Dec       Impact factor: 2.144

10.  Estimation of the target stem-cell population size in chronic myeloid leukemogenesis.

Authors:  T Radivoyevitch; M J Ramsey; J D Tucker
Journal:  Radiat Environ Biophys       Date:  1999-09       Impact factor: 1.925

View more
  5 in total

1.  Sex differences in the incidence of chronic myeloid leukemia.

Authors:  Tomas Radivoyevitch; Gradimir M Jankovic; Ramon V Tiu; Yogen Saunthararajah; Robert C Jackson; Lynn R Hlatky; Robert Peter Gale; Rainer K Sachs
Journal:  Radiat Environ Biophys       Date:  2013-12-13       Impact factor: 1.925

2.  Defining AML and MDS second cancer risk dynamics after diagnoses of first cancers treated or not with radiation.

Authors:  T Radivoyevitch; R K Sachs; R P Gale; R J Molenaar; D J Brenner; B T Hill; M E Kalaycio; H E Carraway; S Mukherjee; M A Sekeres; J P Maciejewski
Journal:  Leukemia       Date:  2015-09-22       Impact factor: 11.528

3.  Evolutionary Dynamics of Chronic Myeloid Leukemia Progression: the Progression-Inhibitory Effect of Imatinib.

Authors:  Robert C Jackson; Tomas Radivoyevitch
Journal:  AAPS J       Date:  2016-03-23       Impact factor: 4.009

4.  Life histories of myeloproliferative neoplasms inferred from phylogenies.

Authors:  Nicholas Williams; Joe Lee; Emily Mitchell; Luiza Moore; E Joanna Baxter; James Hewinson; Kevin J Dawson; Andrew Menzies; Anna L Godfrey; Anthony R Green; Peter J Campbell; Jyoti Nangalia
Journal:  Nature       Date:  2022-01-20       Impact factor: 69.504

5.  Reduced tyrosine kinase inhibitor dose is predicted to be as effective as standard dose in chronic myeloid leukemia: a simulation study based on phase III trial data.

Authors:  Artur C Fassoni; Christoph Baldow; Ingo Roeder; Ingmar Glauche
Journal:  Haematologica       Date:  2018-06-28       Impact factor: 9.941

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.